Analyst firms · Leerink Partners · ALGS
Leerink Partners ALGS price target and rating history
Aligos Therapeutics Inc. (ALGS) · Health Care
Leerink Partners rates Aligos Therapeutics Inc. (ALGS) Outperform with a $11 price target, as of its latest action on Mar 11, 2022. It has published 4 rating actions on ALGS since September 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a ALGS price target in the last 12 months, the median target is $45.
- Current rating
- Outperform
- Price target
- $11
- Median target, all firms
- $45
- Actions on ALGS
- 4
Leerink Partners price target on ALGS
Every Leerink Partners rating on ALGS
- Mar 11, 2022
- Feb 16, 2022
- Jan 7, 2022
- Sep 9, 2021
How other firms rate ALGS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Lake Street | Buy | $45 | May 28, 2026 |
| Cantor Fitzgerald | Overweight | $20 | May 21, 2026 |
| Jefferies | Buy | $48 | Mar 19, 2026 |
Questions about Leerink Partners and ALGS
- What is Leerink Partners's price target for ALGS?
- Leerink Partners's latest stated price target for Aligos Therapeutics Inc. (ALGS) is $11, from its action on Mar 11, 2022.
- What is Leerink Partners's rating on ALGS?
- Leerink Partners rates ALGS Outperform, a bullish rating, as of Mar 11, 2022.
- When did Leerink Partners last change its view on ALGS?
- On Mar 11, 2022, Leerink Partners raises its price target to $11 from $10, keeps Outperform.
- How does Leerink Partners's ALGS target compare with other analysts?
- Across 3 firms with a ALGS price target in the last 12 months, the median target is $45.
More ALGS rating histories
All Leerink Partners ratingsALGS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.